PYRAZOLE MAGL INHIBITORSProvided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.A compound of Formula (I):Formula (I);wherein:R1 is -N(R2)C(0)R15 or -N(H)S02R15;2 is H or Chalky!;A is N or C(H);X is -0-, -N(R16)-, or -CH2N(R16)CH2-;Y is -CH2- or -C(O)-;Z is -S-, -0-, or -N(R20)-;R4 is H, halogen, -OR7, Ci-6alkyl, Ci-6alkyl-OH, C2-6alkenyl, C2-6alkynyl, Ci-6haloalkyl, -O-C3.scycloalkyl, -0-C3-8cycloalkyl-OH, -N(H)-Ci-6alkyl-C02H, -S02R17, -C02R8, -C(0) R8R9, C3-8cycloalkyl, C2-9heterocycloalkyl, -Ci-6alkyl-C2-9heterocycloalkyl, C6-10aryl, Ci.gheteroaryl, wherein C3-8cycloalkyl, C2-9heterocycloalkyl, -Ci-6alkyl-C2-9heterocycloalkyl,C6-i0aryl, Ci-9heteroaryl are optionally substituted with 1 or 2 R14;R5 is H, -CN, halogen, Ci-6alkyl, Ci-6haloalkyl, Ci-6haloalkoxy, or phenyl;R6 is H, halogen, or R7 is H, Ci-6alkyl, Ci-6haloalkyl, C3-8cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, or Ci.gheteroaryl, wherein C2-9heterocycloalkyl, C6-ioaryl, or Ci-9heteroaryl are optionally substituted with 1 or 2 R14;each R8 and each R9 are independently selected from H and or R8 and R9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;R10 is -0-Ci-6haloalkyl, -0-Ci-6alkyl-C02H, -0-C3-8cycloalkyl, -0-C3-8cycloalkyl-C02H, -N(H)-Ci-6alkyl-C02H, or -S02R17;R12 is H, halogen, or R13 is H or Ci-6alkyl;each R14 is independently selected from halogen, -OH, oxo, Ci-6alkyl, Ci-6haloalkyl, Ci-6alkoxy, -Ci-6alkyl-OH, C3-8cycloalkyl, -C02R8, -C(0) R8R9, -C(0)-Ci-6alkyl, -C(0)-Ci-6alkyl-OH, -S02-Ci-6alkyl, -N(R8)S02-Ci-6alkyl, and -N(R8)C(0)-Ci-6alkyl;R15 is Ci-6alkyl or C3-8cycloalkyl;R16 is H, Ci-6alkyl, -C(0)-Ci-6alkyl, or -CH2C02H;R17 is Ci-6alkyl or C3-8cycloalkyl;R18 and R19 are independently selected from H and wherein R18 and R19 are not both H;R20 is H or Ci-6alkyl;v is 0 or 1;n is 0 or 1;m is 0 or 1;p is 0, 1, or 2;q is 0, 1, or 2; andw is 1 or 2;or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof. The compound of claim 1, or a solvate, hydrate, tautomer N-oxide, stereoisomer, orpharmaceutically acceptable salt thereof, wherein R is The compound of claim 2, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, p is 1, and w is 1. The compound of claim 2, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 0, n is 1, p is 1, and w is 2. The compound of claim 2, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, p is 0, and w is 1. The compound of any one of claims 1-5, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein A is C(H).The compound of any one of claims 1-5, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein A is N.The compound of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, orpharmaceutically acceptable salt thereof, wherein R3 is 
피라졸 MAGL 저해제피라졸 화합물 및 상기 화합물을 포함하는 약제학적 조성물이 본 명세서에 제공된다. 본 화합물 및 조성물은 MAGL의 조절제로서 유용하다. 추가로, 본 화합물 및 조성물은 통증의 치료에 유용하다.화학식 I의 화합물, 또는 이의 용매화물, 수화물, 호변이성질체, N-옥사이드, 입체이성질체 또는 약제학적으로 허용 가능한 염:[화학식 I](식 중,R1은 -N(R2)C(O)R15 또는 -N(H)SO2R15이고;R2는 H 또는 C1-6알킬이고;R3은 , , , , , , , , , , ,  또는 이고;A는 N 또는 C(H)이고;X는 -O-, -N(R16)- 또는 -CH2N(R16)CH2-이고;Y는 -CH2- 또는 -C(O)-이고;Z는 -S-, -O- 또는 -N(R20)-이고;R4는 H, 할로겐, -OR7, C1-6알킬, C1-6알킬-OH, C2-6알케닐, C2-6알키닐, C1-6할로알킬, -O-C3-8사이클로알킬, -O-C3-8사이클로알킬-OH, -N(H)-C1-6알킬-CO2H, -SO2R17,-CO2R8, -C(O)NR8R9, C3-8사이클로알킬, C2-9헤테로사이클로알킬, -C1-6알킬-C2-9헤테로사이클로알킬, C6-10아릴, C1-9헤테로아릴이고, 여기서 C3-8사이클로알킬, C2-9헤테로사이클로알킬, -C1-6알킬-C2-9헤테로사이클로알킬, C6-10아릴, C1-9헤테로아릴은 1개 또는 2개의 R14로 선택적으로 치환되고;R5는 H, -CN, 할로겐, C1-6알킬, C1-6할로알킬, C1-6할로알콕시 또는 페닐이고;R6은 H, 할로겐 또는 C1-6알킬이고;R7은 H, C1-6알킬, C1-6할로알킬, C3-8사이클로알킬, C2-9헤테로사이클로알킬, C6-10아릴 또는 C1-9헤테로아릴이고, 여기서 C2-9헤테로사이클로알킬, C6-10아릴 또는 C1-9헤테로아릴은 1개 또는 2개의 R14로 선택적으로 치환되고;각각의 R8 및 각각의 R9는 H 및 C1-6알킬로부터 독립적으로 선택되거나; R8 및 R9는 이들이 부착된 질소와 함께 조합되어 헤테로사이클로알킬 고리를 형성하고;R10은 -O-C1-6할로알킬, -O-C1-6알킬-CO2H, -O-C3-8사이클로알킬, -O-C3-8사이클로알킬-CO2H, -N(H)-C1-6알킬-CO2H 또는 -SO2R17이고;R12는 H, 할로겐 또는 C1-6알킬이고;R13은 H 또는 C1-6알킬이고;각각의 R14는 할로겐, -OH, 옥소, C1-6알킬, C1-6할로알킬, C1-6알콕시, -C1-6알킬-OH, C3-8사이클로알킬, -CO2R8, -C(O)NR8R9, -C(O)-C1-6알킬, -C(O)-C1-6알킬-OH, -SO2-C1-6알킬, -N(R8)SO2-C1-6알킬 및 -N(R8)C(O)-C1-6알킬로부터 독립적으로 선택되고;R15는 C1-6알킬 또는 C3-8사이클로알킬이고;R16은 H, C1-6알킬, -C(O)-C1-6알킬 또는 -CH2CO2H이고;R17은 C1-6알킬 또는 C3-8사이클로알킬이고;R18 및 R19는 H 및 C1-6알킬로부터 독립적으로 선택되고, 여기서 R18 및 R19는 둘 모두 H가 아니고;R20은 H 또는 C1-6알킬이고;v는 0 또는 1이고;n은 0 또는 1이고;m은 0 또는 1이고;p는 0, 1 또는 2이고;q는 0, 1 또는 2이고;w는 1 또는 2임).